Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Diphtheria/Tetanus Toxoids/Acellular Pertussis Vaccine (DTaP/Tdap)»

Diphtheria / Tetanus Toxoids / Acellular Pertussis Vaccine

( DTaP/Tdap ) Pronunciation: (dif-THEER-ee-a/TET-a-nus/aye-SELL-yoo-ler per-TUS-is)Class: Toxoid

Trade Names:Adacel- Injection diphtheria toxoid 2 Lf units, tetanus toxoid 5 Lf units, pertactin 3 mcg, filamentous hemagglutinin (FHA) 5 mcg, detoxified pertussis toxins 2.5 mcg, fimbriae types two and three 5 mcg per 0.5 mL

Trade Names:Boostrix- Injection diphtheria toxoid 2.5 Lf units, tetanus toxoid 5 Lf units, pertactin 2.5 mcg, FHA 8 mcg, inactivated pertussis toxins 8 mcg per 0.5 mL

Trade Names:Daptacel- Injection diphtheria toxoid 15 Lf units, tetanus toxoid 5 Lf units, pertussis toxoid 10 mcg, FHA 5 mcg, pertactin 3 mcg, fimbriae types two and three 5 mcg per 0.5 mL

Trade Names:Infanrix- Injection diphtheria 25 Lf units, tetanus toxoid 10 Lf units, pertussis toxin 25 mcg, FHA 25 mcg, pertactin 8 mcg per 0.5 mL

Trade Names:Tripedia- Injection diphtheria toxoid 6.7 Lf units, tetanus toxoid 5 Lf units, pertussis antigens (approximately 23.4 mcg each of inactivated pertussis toxin and FHA) 46.8 mcg per 0.5 mL


Diphtheria and tetanus toxoids induce antibodies against toxins made by Corynebacterium diphtheriae and Clostridium tetani . Pertussis vaccine protects against Bordetella pertussis .

Indications and Usage

Per CDC, Tdap is for use in adults and children 10 yr of age and older, and DTaP is for use in infants and children younger than 7 yr of age.

Adacel (Tdap)

Active booster immunization against diphtheria, tetanus, and pertussis as a single dose in persons 11 to 64 yr of age.

Boostrix (Tdap)

Active booster immunization against diphtheria, tetanus, and pertussis as a single dose in persons 10 to 64 yr of age.

Daptacel , Infanrix , Tripedia (DTaP)

Active immunization against diphtheria, tetanus, and pertussis in infants and children 6 wk to 6 yr of age (prior to seventh birthday).


Encephalopathy within 7 days of previous administration of any pertussis-containing vaccine that is not attributable to another cause; progressive neurologic disorders (eg, infantile spasms, uncontrolled epilepsy, progressive encephalopathy), in addition, pertussis vaccine should not be administered to persons with these conditions until a treatment regimen has been established and condition has stabilized; hypersensitivity to any component of the vaccine; history of serious allergic reaction temporarily associated with a previous dose of vaccine or any component of the vaccine.

Daptacel , Infanrix , Tripedia

Use in adults or children 7 yr of age and older; if contraindication to pertussis vaccine component occurs, substitute diphtheria and tetanus toxoids for pediatric use (DTaP) for each remaining dose; defer elective immunization procedures during outbreak of poliomyelitis because of risk of provoking paralysis.

Dosage and Administration

It is recommended that the same brand of DTaP ( Daptacel , Infanrix , Tripedia ) be given for all doses in the immunization series because no data exist on the interchangeability of DTaP vaccines. Tdap vaccines ( Adacel , Boostrix ) are not interchangeable with DTaP vaccines.

Adacel (Tdap)Adults and Children 11 yr of age and older

IM 0.5 mL.

Boostrix (Tdap)Adults and Children 10 to 64 yr of age

IM 0.5 mL.

Daptacel (DTaP)Infants and Children 6 wk to 6 yr of age (prior to seventh birthday)

IM Immunization is 4-dose series of 0.5 mL at 2, 4, and 6 mo of age at intervals of 6 to 8 wk, and at the fourth dose at 15 to 20 mo of age. Interval between third and fourth dose should be 6 to 12 mo.

Infanrix (DTaP)Infants and Children 6 wk to 6 yr of age (prior to seventh birthday)

IM Immunization consists of a 5-dose series. A primary immunization course involves 3 doses administered at 2, 4, and 6 mo of age, followed by 2 booster doses administered at 15 to 20 mo of age and at 4 to 6 yr of age. The customary age for the first dose is 2 mo of age, but it may be given as early as 6 wk of age. The recommended interval between the first 3 doses is 8 wk, with a minimum interval of 4 wk. The recommended interval between the third and fourth dose is 6 to 12 mo. The fifth dose is recommended before entry into kindergarten or elementary school. If the fourth dose is given after the fourth birthday, a fifth dose is not necessary.

Tripedia (DTaP)Infants and Children 6 wk to 6 yr of age

IM Immunization consists of a 5-dose series. Primary immunization series is 3 doses administered at 2, 4, and 6 mo of age, followed by 2 booster doses administered at 15 to 18 mo and at 4 to 6 yr of age. The customary age for the first dose is 2 mo, but it may be given as early as 6 wk. The recommended interval between the first 3 doses is 8 wk, with a minimum interval of 4 wk. The recommended interval between the third and fourth dose is 6 to 12 mo. The fifth dose is recommended before entry into kindergarten or elementary school. If the fourth dose was given after the fourth birthday, a fifth dose prior to school entry is not necessary.

General Advice

  • For IM administration only. Not for intradermal, subcutaneous, IV, or intra-arterial administration.
  • Have epinephrine injection and other appropriate agents and equipment immediately available should an acute anaphylactic reaction occur.
  • Attempt to use the same brand of vaccine for the entire series; however, when this is not possible, use any DTaP vaccine to continue or complete series.
  • Interruption of recommended schedule with a delay between doses does not interfere with development of final immunity. There is no need to start the series over again.
  • Use vaccine as supplied; no dilution or reconstitution is necessary. Do not mix with any other vaccine in the same vial or syringe.
  • Shake vial or syringe vigorously immediately prior to use to obtain a uniform suspension. Suspension should be homogeneous and white. Do not use if particulate matter or discoloration are noted or if vaccine cannot be resuspended.
  • Rotate vial or syringe in palm to bring contents to room temperature before administering; administer immediately.
  • Discard any vaccine remaining in vial after withdrawing dose.
  • Administer IM in anterolateral thigh in infants (younger than 1 yr of age) or deltoid muscle of upper arm (for older children and adults). Avoid injection into gluteal area or areas where there may be a major nerve trunk or blood vessel.
  • May administer vaccine in conjunction with injectable polio, Haemophilus influenza type b, hepatitis B, varicella, and measles, mumps, pneumococcal conjugate, and rubella virus vaccines using separate syringes and different sites for administration.
  • Tripedia may be used to reconstitute Haemophilus b conjugate vaccine for administration of fourth dose to children 15 to 18 mo of age.
  • Adacel : 5 yr should have elapsed since the person's last dose of tetanus toxoid, diphtheria, and/or pertussis–containing vaccine.
  • Always record manufacturer's name and vaccine lot number in patient's permanent medical record file, along with date of administration, and name and title of person administering vaccine.


Store vials and syringes in refrigerator (35° to 46°F). Do not freeze. Discard if vaccine has been frozen.

Drug Interactions


Give DTaP/Tdap with caution to patients on anticoagulant therapy.

Immunosuppressants (eg, alkylating agents, antimetabolites, corticosteroids, cytotoxic agents, irradiation)

May reduce efficacy of the vaccine.

Influenza vaccine

To attribute causality of adverse reactions, do not give influenza vaccine within 3 days of pertussis vaccination.


Do not mix in the same syringe or vial with other vaccines.

Laboratory Test Interactions

None well documented.

Adverse Reactions



Myocarditis (postmarketing).


Myocarditis (postmarketing).


Cyanosis (postmarketing).


Cyanosis (postmarketing).



Headache (44%); tiredness (30%); convulsions, hyposthesia, facial palsy, paresthesia, syncope (postmarketing).


Headache (43%); fatigue (37%); convulsion, encephalitis, facial palsy, paresthesia (postmarketing).


Fussiness (76%); fretfulness (40%); drowsiness (33%); anorexia (11%); convulsions, febrile convulsion, grand mal convulsion, hypotonia, hypotonic-hyporesponsive episode, partial seizures, screaming, somnolence (postmarketing).


Drowsiness (38%); anorexia (12%); fussiness (9%); convulsions, encephalopathy, hypotonia, hypotonic-hyporesponsive episode, irritability, somnolence (postmarketing).


Drowsiness (42%); irritability (35%); fussiness (19%); loss of appetite (15%); anorexia (10%); vomiting (6%).



Rash (3%); pruritus, urticaria (postmarketing).


Exanthem, Henoch-Schonlein purpura, rash, urticaria (postmarketing).


Erythema, pruritus, rash, urticaria (postmarketing).



Ear pain (postmarketing).



Nausea (13%); diarrhea (10%); vomiting (5%).


GI symptoms including abdominal pain, diarrhea, nausea, vomiting (26%).


Vomiting (7%); diarrhea, nausea (postmarketing).


Vomiting (7%); diarrhea, intussusception (postmarketing).


Anorexia (22%); vomiting (7%); diarrhea (6%).



Lymph node swelling (7%).


Lymphadenitis, lymphadenopathy (postmarketing).


Idiopathic thrombocytopenic purpura, lymphadenopathy, thrombocytopenia (postmarketing).



Anaphylactic reaction, hypersensitivity reaction including angioedema, edema, hypotension, rash (postmarketing).


Anaphylactic reaction, arthus-type hypersensitivity.


Allergic reaction, anaphylactic reaction (edema, face edema, face swelling, generalized rash and other types of rash, pruritus), hypersensitivity (postmarketing).


Anaphylactic reaction, hypersensitivity (postmarketing).



Pain (78%); erythema (25%); swelling (21%); injection-site bruising, sterile abscess (postmarketing).


Pain (75%); redness (48%); swelling (39%); increase in arm circumference (28%); induration, inflammation, local reaction, mass, nodule, warmth (postmarketing).


Tenderness (50%); increased arm circumference (30%); redness (17%); swelling (12%); cellulitis, injection-site abscess, injection-site mass, injection-site nodule, injection-site pain, injection-site rash (postmarketing).


Redness (59%); swelling (50%); pain (27%); injection-site reactions (postmarketing).


Tenderness (46%); erythema, redness (39%); swelling (29%); pain (21%); tenderness (12%).



Body ache or muscle weakness (30%); sore and swollen joints (11%); muscle spasms, myelitis, myositis (postmarketing).


Arthralgia, back pain, myalgia (postmarketing).


Limb swelling (postmarketing).



Respiratory tract infection (postmarketing).



Chills (15%); fever (5%).


Fever (14%).


Crying (59%); decreased activity (51%); fever (24%).


Fever (7%); cellulitis, crying, sudden infant death syndrome (postmarketing).


Fever (25%); crying (2%).



When child returns for next dose in series, question parent or guardian about serious adverse reactions with previous dose. Note any adverse reactions that would contraindicate additional pertussis vaccine; if reactions are observed, complete immunization series with diphtheria and tetanus toxoids adsorbed (DT). If any event listed in the US Department of Health and Human Services' Vaccine Injury Table or other serious adverse reactions occur, report them through the Vaccine Adverse Event Reporting System (VAERS) per organizational policy.


Category C .





Safety and efficacy not established in children younger than 11 yr of age.


Not indicated for use in patients younger than 10 yr of age.

Daptacel , Infanrix , Tripedia

Safety and efficacy in infants younger than 6 wk of age not established; not for use in persons 7 yr of age and older.


Adacel , Boostrix

Safety and efficacy not established in persons 65 yr of age and older.

Special Risk Patients

If any of the following occurs in temporal relation with receipt of either whole-cell pertussis DTP or DTaP, carefully consider decision to administer subsequent doses of vaccine containing pertussis component: temperature of at least 105°F within 48 h not caused by another identifiable cause; collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 h; persistent inconsolable crying lasting at least 3 h and occurring within 48 h; or convulsions, with or without fever, occurring within 3 days. If the decision is made to withhold pertussis component, continue immunization with DT (Td if 7 yr of age and older).


Vaccination should generally be deferred in the following situations: moderate or severe acute illness with or without fever, until the acute illness resolves; in adolescents, progressive neurologic disorder, including progressive encephalopathy or uncontrolled epilepsy, until the condition has stabilized; in adults, unstable neurologic condition (eg, cerebrovascular events and acute encephalopathic conditions) until the condition has resolved or stabilized.

Arthus-type hypersensitivity

Persons who experience an Arthus-type hypersensitivity reaction following prior administration of a tetanus toxoid–containing vaccine usually have a high serum tetanus antitoxin level and should not receive a tetanus toxoid-containing vaccine unless at least 10 years have elapsed since the last dose of a tetanus–containing vaccine.

Bleeding disorders

Use with caution in patients with bleeding disorders (eg, hemophilia, thrombocytopenia) or who are receiving anticoagulant therapy.

Convulsions/CNS disorders

Family history of seizures or other CNS disorders is not a contraindication to pertussis vaccine.

Febrile illness or acute infection

Defer immunization during course of illness. Minor respiratory illness, such as mild upper respiratory tract infection, is usually not a reason to defer immunization.

Guillain-Barré syndrome and brachial neuritis

If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the decision to give subsequent doses of any tetanus toxoid–containing vaccine should be based on careful consideration of the potential benefits and possible risks. There is a causal relationship between administration of tetanus toxoid and both brachial neuritis and Guillain-Barré syndrome.


May have diminished antibody response; defer immunization, if possible, until immunocompetency is restored.

Latex sensitivity

Stoppers for Daptacel and Tripedia vials, and tip cap and rubber plunger of Infanrix and Boostrix needleless prefilled syringes contain dry natural latex rubber that may cause allergic reactions in latex-sensitive persons.

Neurologic disorders

Progressive neurologic disorder, uncontrolled epilepsy, progressive encephalopathy, or unstable neurological conditions are considered reasons to defer DTaP vaccination.



None noted.

Patient Information

  • Explain name, action, and potential adverse reactions of vaccine. Review benefits and risks of the vaccine and importance of completing the immunization series.
  • Provide and review the Vaccine Information Statements prior to immunization.
  • Review immunization schedule.
  • Provide parent or guardian with immunization history record and record this immunization in patient's immunization record.
  • Advise patient, or parent or guardian of child with history of seizures or family member with seizure disorder that controlling fever after vaccination is very important. Advise parent or guardian to give the child an aspirin-free pain reliever (eg, acetaminophen, ibuprofen) when the shot is given and for the next 24 h, following package instructions.
  • Advise parent or guardian that the following problems occur frequently within 1 to 3 days after vaccination but are generally mild: fussiness, poor appetite, tiredness, vomiting.
  • Advise patient, parent, or guardian to use non-aspirin-containing OTC analgesics (eg, acetaminophen, ibuprofen) for fever, pain, or discomfort at injection site.
  • Immediately notify health care provider if: vaccine recipient develops fever of 105°F or more, faints, persistently cries for more than 3 h within 48 h of receiving vaccine, has a seizure with or without fever within 7 days of receiving vaccine.
  • Instruct parent or guardian to immediately notify health care provider if change in mental alertness or unresponsiveness occurs within 7 days of receiving vaccination.

Copyright © 2009 Wolters Kluwer Health.

Comment «Diphtheria/Tetanus Toxoids/Acellular Pertussis Vaccine (DTaP/Tdap)»